Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - ... 5 - 6 - 7 - 8 - 9 - 10 - 11 - ...
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: bimekizumab pipeline update in PsA

Bimekizumab demonstrates impressive joint and skin responses for psoriatic arthritis patientsPositive top line results from the UCB Phase 2b BE ACTIVE study underscore the potential of bimekizumab to significantly improve joint and skin symptoms in PsA patientsThe study achieved a stringent primary endpoint, with up to 46% of psoriatic arthritis PsA patients who received bimekizumab experiencing... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: bimekizumab pipeline update in AS

Bimekizumab advances with significant results in ankylosing spondylitis patientsPositive first results in ankylosing spondylitis from the UCB Phase 2b BE AGILE study of bimekizumab show statistical significance in multiple dose groupsThe study achieved the primary endpoint ASAS40, with up to 47% of patients receiving bimekizumab achieving at least 40% improvement in ankylosing spondylitis AS... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: AES Curtain Raiser

UCB showcases new research and continued epilepsy leadership at the 2017 American Epilepsy Society Annual MeetingUCB reinforces commitment to delivering improved patient value by presenting latest epilepsy research findings25 scientific presentations illustrate and reinforce UCB’s dedication to improving patient value in epilepsyCongress also provides platform for collaboration, ideation and... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: New study data presented at ISPOR

New study data shows prior osteoporotic fractures put women at increased risk of future major osteoporotic fracturesRisk of a subsequent fracture was highest within the first two years after the previous fracture according to Swedish observational study1Prior vertebral fracture led to a higher risk of subsequent fracture compared to prior hip or any other fragility fracture1BRUSSELS, Belgium 8th... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: UCB Dermira Collaboration

Dermira and UCB Agree to End Collaboration Agreement for CIMZIADermira to transition development and commercialization responsibility for CIMZIA® certolizumab pegol in psoriasis back to UCBDecision reflects both companies’ strategic prioritiesUCB remains committed to bringing CIMZIA to psoriasis patients upon regulatory approvalMENLO PARK, Calif. and BRUSSELS, Belgium, Nov. 6, 2017 –... See more